Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Arienti

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion moleculesF Arienti, C Gambacorti-Passerini, L Borin, et al.
European Journal of Neurology|May 14, 2020
Systemic involvement in adult-onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome) with a novel mutation of the SNORD118 geneG Bonomo, E Monfrini, L Borellini, et al.
Natural Immunity|March 1, 1994
Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cellsC Melani, C Chiodoni, F Arienti, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotypeL Rivoltini, F Arienti, A Orazi, et al.
Tumori|December 31, 1991
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patientsS Spinazzé, S Viviani, P Bidoli, et al.
Melanoma Research|November 1, 1992
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot studyF Belli, F Arienti, L Rivoltini, et al.
International Journal of Cancer|November 3, 1995
Expression of MAGE genes in primary and metastatic cutaneous melanomaF Brasseur, D Rimoldi, D Liénard, et al.
Cancer Research|August 1, 1995
Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomasS Salvi, F Segalla, S Rao, et al.
Annals of Surgical Oncology|January 1, 1995
Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanomaM Vaglini, F Belli, M Santinami, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1993
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2F Arienti, F Belli, L Rivoltini, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion moleculesF Arienti, C Gambacorti-Passerini, L Borin, et al.
European Journal of Neurology|May 14, 2020
Systemic involvement in adult-onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome) with a novel mutation of the SNORD118 geneG Bonomo, E Monfrini, L Borellini, et al.
Natural Immunity|March 1, 1994
Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cellsC Melani, C Chiodoni, F Arienti, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotypeL Rivoltini, F Arienti, A Orazi, et al.
Tumori|December 31, 1991
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patientsS Spinazzé, S Viviani, P Bidoli, et al.
Melanoma Research|November 1, 1992
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot studyF Belli, F Arienti, L Rivoltini, et al.
International Journal of Cancer|November 3, 1995
Expression of MAGE genes in primary and metastatic cutaneous melanomaF Brasseur, D Rimoldi, D Liénard, et al.
Cancer Research|August 1, 1995
Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomasS Salvi, F Segalla, S Rao, et al.
Annals of Surgical Oncology|January 1, 1995
Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanomaM Vaglini, F Belli, M Santinami, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1993
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2F Arienti, F Belli, L Rivoltini, et al.
Pageof 4